Personalized targeted treatment selection for metastatic cancer patients through full blood volume tumor cell analysis.

Gemini Theranostics developed a theranostic platform targeting the Follicle Stimulating Hormone Receptor (FSHR), a therapeutic target that is expressed in 50-70% of ovarian cancer patients.

Next-generation gene promoters for more stable and higher recombinant protein expression.

Pionering whole genome sequencing based genotoxicity testing

A robust patient monitoring device which is highly reliable and easy to use to prevent children in low and middle income countries unnecessary dying from severe bacterial infections.

HeartSmart revolutionizes cardiac research with a miniaturized heart tissue model that accurately mimics fibrosis and enables reliable, predictive drug testing for heart failure therapies.

HELIA Biomonitoring’s mission is to enable continuous monitoring of therapeutic drug concentrations, organ function markers, and treatment response markers for personalized patient care.

Liver toxicity is the main safety reason for drug attrition in clinical trials, causing 1 in every 13 drugs to fail. We have developed a novel, human liver model in a dish called hello which accurately predicts the toxicity of drugs.

At Hybridize, we have developed a cost-effective proprietary therapeutic compound that can be intravenously administered to protect the kidney from BKV-mediated damage while maintaining full immunosuppression.

Basal cell carcinoma is the most diagnosed cancer worldwide. IMcoMET is developing a novel treatment method that will lead to removal of lesions with only minor side effects.